Afelimomab
Monoclonal antibody
NY (what is this?) (verify) Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
References
- ^ Rondon E, Venkataraman R (August 2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
- ^ Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. (November 2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–82. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628. S2CID 23321488.
- v
- t
- e
Immunosuppressive drugs / Immunosuppressants (L04)
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors |
|
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan
- Deucravacitinib
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e